A tumor radiation probe of iodine-123 marker thymidine (FLT) analogue [123I]-IaraU is disclosed. Commercial available uridine is used as the raw material for the synthesis of the precursor. A radioactive iodine-123 is marked on an alkaline group of uridine to obtain [123I]-IaraU, which is distinguishable from [18F]-FLT marking 18F on a glycosyl group to obtain a novel tumor radiation probe. The marking procedures include mixing the marker precursor with Na [123I] solution, acetic acid and hydrogen peroxide solution, and the solution of chloroform and sodium hydroxide. The sonication time increases from 1 minute to 10 minutes, so that [123I]-IaraU has radiologically chemical purity of higher than 98% and radiological specific activity of not less than 0.196 GBq/umole, and the yield can increase from 8% to 40%. Its radioactive specific activity, yield and purity reach to the degree for the use in biological experiments, while reducing production cost.
本文介绍了一种以
碘-123标记胸腺
嘧啶(FLT)类似物[123I]-IaraU的肿瘤放射探针。商业可用的尿
嘧啶作为前体合成的原料。将放射性
碘-123标记在尿
嘧啶的碱性基团上,得到[123I]-IaraU,与将18F标记在糖基上的[18F]-FLT有所区别,从而获得一种新的肿瘤放射探针。标记过程包括将标记前体与Na [123I]溶液、
乙酸和
过氧化氢溶液以及
氯仿和
氢氧化钠溶液混合。超声时间由1分钟增加到10分钟,使[123I]-IaraU具有放射
化学纯度高于98%和放射特异活度不低于0.196 GBq / umole,产率可从8%提高到40%。其放射性特异活度、产率和纯度达到了用于
生物实验的要求,同时降低了生产成本。